IDEAYA Biosciences (IDYA) RBC Capital Markets Global Healthcare Conference 2025 summary

Key program updates and clinical milestones

• Anticipates a transformational year with four major data readouts for Darovasertib in uveal melanoma, including randomized PFS and OS data by year-end 2025.

• Neoadjuvant uveal melanoma data will be presented mid-year and in the second half, with eye preservation rates already exceeding 50%.

• Plans to launch a registrational neoadjuvant study, targeting both HLA-A2 negative and positive populations, with NDA submissions planned based on top-line results.

• Pipeline includes phase II MAT2A inhibitor, PRMT5 inhibitor entering clinic, DLL3 ADC in phase I, and three additional INDs expected by year-end.

• FDA Breakthrough Therapy Designation received for neoadjuvant setting, with pivotal phase III studies aiming for rapid enrollment and sequential readouts.

Commercialization and market strategy

• Focused on achieving first commercial product with Darovasertib, initially targeting HLA-A2 negative metastatic uveal melanoma for Accelerated Approval.

• Plans to leverage real-world evidence and concurrent NDA submissions to expand into HLA-A2 positive population and secure US pricing and reimbursement.

• No plans for head-to-head studies with KIMMTRAK; confident in agent activity both pre- and post-KIMMTRAK treatment.

• Pricing strategy considers rare cancer status and lack of approved therapies, using existing large molecule analogs as benchmarks.

• Neoadjuvant population expected to be at least double the metastatic population, with significant upside from targeting prevalence pool.

Pipeline diversification and future outlook

• DLL3 ADC (IDE849) shows promising monotherapy activity with 70%+ response rate; phase I data and expansion dose selection expected to accelerate development.

• Global strategy includes collaboration with HUTCHMED for rapid advancement and regulatory submissions in China and worldwide.

• Frontline small cell lung cancer studies planned, replacing etoposide with ADC in combination regimens.

• MAT2A/PRMT5 combination and Werner inhibitor highlighted as potential best-in-class assets, with multiple new programs in discovery.

• Platform approach aims to deliver additional agents beyond current pipeline, supporting long-term growth in precision oncology.